Purpose: To compare the efficacy of behavioral activation (BA) plus low vision rehabilitation with an occupational therapist (OT-LVR) with supportive therapy (ST) on visual function in patients with age-related macular degeneration (AMD).
Methods: Single-masked, attention-controlled, randomized clinical trial with AMD patients with subsyndromal depressive symptoms (n = 188). All subjects had two outpatient low vision rehabilitation optometry visits, then were randomized to in-home BA + OT-LVR or ST. Behavioral activation is a structured behavioral treatment aiming to increase adaptive behaviors and achieve valued goals. Supportive therapy is a nondirective, psychological treatment that provides emotional support and controls for attention. Functional vision was assessed with the activity inventory (AI) in which participants rate the difficulty level of goals and corresponding tasks. Participants were assessed at baseline and 4 months.
Results: Improvements in functional vision measures were seen in both the BA + OT-LVR and ST groups at the goal level (d = 0.71; d = 0.56 respectively). At the task level, BA + OT-LVR patients showed more improvement in reading, inside-the-home tasks and outside-the-home tasks, when compared to ST patients. The greatest effects were seen in the BA + OT-LVR group in subjects with a visual acuity ≥20/70 (d = 0.360 reading; d = 0.500 inside the home; d = 0.468 outside the home).
Conclusions: Based on the trends of the AI data, we suggest that BA + OT-LVR services, provided by an OT in the patient's home following conventional low vision optometry services, are more effective than conventional optometric low vision services alone for those with mild visual impairment. (ClinicalTrials.gov number, NCT00769015.).
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5361587 | PMC |
http://dx.doi.org/10.1167/iovs.16-20001 | DOI Listing |
Alzheimers Dement
December 2024
UMass Chan Medical School, Worcester, MA, USA.
Background: Almost all primary care providers (PCPs) believe screening for mild cognitive impairment (MCI) and dementia in older patients is important. However, there are significant barriers in primary care, including low provider confidence in their assessment skills, time constraints, competing priorities, and poor financial incentives. Consequently, PCPs report conducting cognitive assessments for less than half of patients over 60 years of age.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
McMaster University, Hamilton, ON, Canada.
Background: 65% of persons with dementia (PWD) suffer from disturbed sleeping patterns and 28% experience vision related falls. Improved lighting has been shown in numerous studies since the 1980s to mitigate these effects.
Method: Computer code was written to optimize the spectra and intensity of light for vision and non-vision purposes over a 24-hour cycle based on off-the-shelf LEDs.
J Ophthalmol
December 2024
Department of Optics & Optometry & Vision Sciences, University of Valencia, Valencia, Spain.
This study aims to analyze the prevalence and severity of posterior capsule opacification (PCO) and glistening in a new hydrophobic biaspheric monofocal intraocular lens (IOLs) 24 months after implantation. By means of a ambispective, observational, case-control design, a total of 297 eyes from 200 cataract surgery patients were included in the study (118 females and 82 males; mean age: 72.31 ± 9.
View Article and Find Full Text PDFProc ACM Symp User Interface Softw Tech
October 2024
Department of Computer Science, Stony Brook University New York, USA.
While gesture typing is widely adopted on touchscreen keyboards, its support for low vision users is limited. We have designed and implemented two keyboard prototypes, layout-magnified and key-magnified keyboards, to enable gesture typing for people with low vision. Both keyboards facilitate uninterrupted access to all keys while the screen magnifier is active, allowing people with low vision to input text with one continuous stroke.
View Article and Find Full Text PDFMol Pharm
January 2025
School of Pharmacy, University of Eastern Finland, Yliopistonranta 1 C, 70210 Kuopio, Finland.
Glaucoma is a vision-threatening disease that is currently treated with intraocular-pressure-reducing eyedrops that are instilled once or multiple times daily. Unfortunately, the treatment is associated with low patient adherence and suboptimal treatment outcomes. We developed carbonic anhydrase II inhibitors (CAI-II) for a prolonged reduction of intraocular pressure (IOP).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!